Wang_2025_Bot.Stud_66_13

BACKGROUND: Mangosteen (Garcinia mangostana L.) pericarp extract has demonstrated potential against Alzheimer's disease (AD) and diabetes mellitus (DM). This study introduces a rapid dereplication and comparative approach to identify and characterize acetylcholinesterase (AChE) and alpha-glucosidase inhibitors in mangosteen pericarp. Using protein-subtraction, MS profiling, and computational modeling is effective for screening, identifying, and analyzing enzyme-inhibiting compounds from plant sources, and quantitative analysis of the main components has been performed. RESULTS: The Mangosteen pericarp extract observed significant inhibitory activity against alpha-glucosidase and AChE, with IC50 values of 31.02 and 70.56 microg/mL, respectively. By comparing profiles of protein-subtracted extracts with non-treated extracts, eight potential inhibitors for each enzyme were identified: 8-desoxygartanin, gartanin, 3-isomangostin, beta-mangostin, 9-hydroxycalabaxanthone, gamma-mangostin, alpha-mangostin, and garcinone E. The alpha-mangostin was the most abundant, comprising 39.589% of the extract. Molecular docking revealed these inhibitors target the peripheral anionic site of AChE and the active site of alpha-glucosidase, forming key hydrogen bonds and pi-pi stacking interactions. CONCLUSION: This study emphasizes mangosteen pericarp as a promising natural source of these inhibitors, with potential for use in developing nutraceuticals and pharmaceuticals. The study validated a systems biology approach by applying dereplication and comparative UPLC-ESI-MS/MS metabolomics profiling to identify target-binding molecules in both protein-treated and untreated plant extracts. Further confirmation was obtained through molecular docking predictions, mechanism analysis, and compound quantification assays.